BioAge Labs Inc.(BIOA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIOA BioAge Labs Inc.

盘前交易 05-14 08:08:17 EDT

19.14

+0.95

+5.22%

盘前19.50

+0.36+1.88%

07:54 EDT

最高19.37	最低17.58	成交量54.17万
今开18.55	昨收18.19	日振幅9.84%
总市值8.49亿	流通市值5.47亿	总股本4,438万
成交额1,005万	换手率1.90%	流通股本2,858万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":19.14,"timestamp":1778702400000,"preClose":18.19,"halted":0,"volume":541690,"hourTrading":{"tag":"盘前","latestPrice":19.5,"preClose":19.14,"latestTime":"07:54 EDT","volume":1964,"amount":38032.192240000004,"timestamp":1778759644062,"change":0.36,"changeRate":0.018809,"amplitude":0.036573},"delay":0,"changeRate":0.05222649807586582,"floatShares":28575500,"shares":44379800,"eps":-2.392358,"marketStatus":"盘前交易","change":0.95,"latestTime":"05-14 08:08:17 EDT","open":18.55,"high":19.37,"low":17.58,"amount":10045457.95878,"amplitude":0.098406,"askPrice":20.1,"askSize":40,"bidPrice":18.51,"bidSize":107,"shortable":3,"etf":0,"ttmEps":-2.392358,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778765400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":19.14,"preHourTrading":{"tag":"盘前","latestPrice":19.5,"preClose":19.14,"latestTime":"07:54 EDT","volume":1964,"amount":38032.192240000004,"timestamp":1778759644062,"change":0.36,"changeRate":0.018809,"amplitude":0.036573},"postHourTrading":{"tag":"盘后","latestPrice":19.4705,"preClose":19.14,"latestTime":"19:38 EDT","volume":6056,"amount":116180.151,"timestamp":1778715498719,"change":0.3305,"changeRate":0.017268,"amplitude":0.020899},"volumeRatio":1.498146711096455,"impliedVol":0.9574,"impliedVolPercentile":0.676},"requestUrl":"/m/hq/s/BIOA","defaultTab":"news","newsList":[{"id":"2633450364","title":"BioAge Labs一季度GAAP每股亏损0.52美元，营收280万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633450364","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633450364?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:45","pubTimestamp":1778251500,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司BioAge Labs公布2026年第一季度财报，GAAP每股亏损0.52美元，营收280万美元。业绩符合公司此前给出的指引区间。　　财报显示，公司一季度净亏损约2100万美元，较上年同期净亏损1800万美元有所扩大。研发费用为1800万美元，同比增长15%，主要因主打药物BGE-303治疗肥胖症的二期临床试验推进。　　首席执行官在声明中表示，BGE-303的二期临床试验进展顺利，公司对数据充满期待。　　财报发布后，BioAge股价在盘后交易中上涨约2%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfanc4135134.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["UDN","BIOA","UUP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100274337","title":"BioAge Labs Inc. 旗下BGE-102在肥胖症治疗中实现突破：120毫克与60毫克剂量组hsCRP中位降幅均超85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1100274337","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100274337?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:06","pubTimestamp":1776769561,"startTime":"0","endTime":"0","summary":"生物医药公司BioAge Labs Inc. 近日公布其核心候选药物BGE-102在肥胖症领域的积极数据。临床研究结果显示，无论是120毫克还是60毫克剂量组，BGE-102均展现出卓越的疗效，能够将超敏C反应蛋白（hsCRP）的中位水平显著降低，降幅达到或超过85%这一关键阈值。\nhsCRP作为体内炎症的关键生物标志物，其水平与肥胖相关的代谢紊乱及心血管疾病风险密切相关。此次数据表明，BGE-102在有效调控炎症通路方面潜力巨大，为肥胖及其并发症的治疗提供了新的可能方向。这一成果不仅验证了药物的作用机制，也为其后续临床开发奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152765977","title":"BioAge Labs Inc公布BGE-102一期临床试验积极中期数据，计划2026年上半年启动2a期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1152765977","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152765977?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:10","pubTimestamp":1774357815,"startTime":"0","endTime":"0","summary":"生物制药公司BioAge Labs Inc近日披露了其候选药物BGE-102的一期临床试验积极中期结果。数据显示，该药物在安全性及耐受性方面表现良好，为后续临床开发奠定基础。\n公司宣布，基于当前数据进展，计划于2026年上半年启动针对特定适应症的2a期临床试验。这一时间表反映出企业正按既定战略推进该药物的临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126957664","title":"BioAge Labs公布2025财年全年业绩及第四季度业务进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1126957664","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126957664?lang=zh_cn&edition=full","pubTime":"2026-03-24 21:01","pubTimestamp":1774357275,"startTime":"0","endTime":"0","summary":"生物科技公司BioAge Labs Inc.近日披露了2025财年完整财务数据，并同步分享了第四季度关键业务动态。财报显示，公司在报告期内持续推进核心研发项目，并在临床研究方面取得阶段性成果。管理层表示，未来将聚焦于管线药物的商业化布局，同时优化资本结构以支持长期发展战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605122202","title":"Bioage Labs, Inc.盘中异动 早盘股价大跌5.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605122202","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605122202?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:30","pubTimestamp":1768919446,"startTime":"0","endTime":"0","summary":"北京时间2026年01月20日22时30分，Bioage Labs, Inc.股票出现异动，股价快速下挫5.45%。Bioage Labs, Inc.股票所在的制药行业中，整体涨幅为0.00%。Bioage Labs, Inc.公司简介：Bioage Labs Inc是一家临床阶段的生物制药公司，通过针对人类衰老生物学，开发针对代谢性疾病（如肥胖）的治疗性产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012022304697a29e50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012022304697a29e50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175648322","title":"BioAge宣布扩大口服NLRP3抑制剂BGE-102适应症范围，拟于2026年中启动针对糖尿病黄斑水肿患者的1b/2a期概念验证临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1175648322","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175648322?lang=zh_cn&edition=full","pubTime":"2026-01-20 22:10","pubTimestamp":1768918239,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc.近日公布其口服NLRP3抑制剂BGE-102的适应症拓展计划。该企业拟于2026年中期启动一项针对糖尿病黄斑水肿患者的1b/2a期概念验证临床试验，旨在评估BGE-102在该疾病领域的治疗潜力。\n此次适应症扩展标志着BioAge在炎症性疾病治疗领域的战略布局进一步深化。糖尿病黄斑水肿作为糖尿病常见的视网膜并发症，目前临床治疗选择仍存在局限性，BGE-102的介入有望为患者提供新的治疗方向。\n临床试验将重点验证BGE-102通过抑制NLRP3炎症小体通路，在缓解视网膜炎症和血管渗漏方面的疗效。若试验结果达到预期，将为企业后续的产品管线拓展奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603632661","title":"Bioage Labs, Inc.盘中异动 股价大跌5.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603632661","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603632661?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:30","pubTimestamp":1768314642,"startTime":"0","endTime":"0","summary":"北京时间2026年01月13日22时30分，Bioage Labs, Inc.股票出现波动，股价急速下跌5.83%。Bioage Labs, Inc.股票所在的制药行业中，整体涨幅为0.00%。其相关个股中，Biofrontera Inc.、Cardiol Therapeutics Inc.、Painreform Ltd.涨幅较大，Akanda Corp.、Gelteq Limited、苏轩堂较为活跃，换手率分别为12.51%、4.90%、3.44%，振幅较大的相关个股有苏轩堂、Bioage Labs, Inc.、Gelteq Limited，振幅分别为8.36%、6.44%、5.71%。Bioage Labs, Inc.公司简介：Bioage Labs Inc是一家临床阶段的生物制药公司，通过针对人类衰老生物学，开发针对代谢性疾病（如肥胖）的治疗性产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113223042a7163e7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113223042a7163e7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142654061","title":"BioAge公布BGE-102一期临床新数据：脑渗透NLRP3抑制剂展现卓越降HSCRP潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1142654061","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142654061?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:17","pubTimestamp":1768227479,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc. 最新发布其候选药物BGE-102的一期临床试验补充积极中期数据。该药物作为一种创新型脑渗透性NLRP3抑制剂，在心血管风险升高受试者中表现出降低超敏C反应蛋白的同类最佳潜力。\n试验结果显示，BGE-102耐受性良好，安全性特征优异。公司预计将于2026年上半年获得完整一期临床数据，并计划同期启动二期A阶段研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193536625","title":"BioAge公布BGE-102一期临床试验新增积极中期数据：新型脑渗透性NLRP3抑制剂展现降低心血管高风险受试者hsCRP的同类最优潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=1193536625","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193536625?lang=zh_cn&edition=full","pubTime":"2026-01-12 22:03","pubTimestamp":1768226631,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc.今日公布了其候选药物BGE-102的额外积极一期临床试验中期数据。BGE-102是一种新型的、具有脑渗透性的NLRP3抑制剂。最新数据显示，该药物在具有高心血管风险的受试者中，表现出可能成为同类最佳（best-in-class）的超敏C反应蛋白（hsCRP）降低潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600196580","title":"Bioage Labs, Inc.盘中异动 下午盘快速跳水5.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2600196580","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600196580?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:01","pubTimestamp":1767380461,"startTime":"0","endTime":"0","summary":"北京时间2026年01月03日03时01分，Bioage Labs, Inc.股票出现异动，股价大幅跳水5.29%。Bioage Labs, Inc.股票所在的制药行业中，整体跌幅为0.67%。其相关个股中，Shuttle Pharmaceuticals Holdings, Inc.、Ironwood医药、Biofrontera Inc.涨幅较大，Akanda Corp.、Ironwood医药、Biofrontera Inc.较为活跃，换手率分别为193.97%、49.07%、48.54%，振幅较大的相关个股有Ironwood医药、Shuttle Pharmaceuticals Holdings, Inc.、Caring Brands, Inc.，振幅分别为46.88%、30.56%、21.14%。Bioage Labs, Inc.公司简介：Bioage Labs Inc是一家临床阶段的生物制药公司，通过针对人类衰老生物学，开发针对代谢性疾病（如肥胖）的治疗性产品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103030101a6ec60b6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260103030101a6ec60b6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BIOA","BFRI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145542124","title":"BioAge Labs Inc - Bge-102在SAD和初始MAD队列中的耐受性良好，药代动力学特征支持每日一次口服给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1145542124","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145542124?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:10","pubTimestamp":1764857410,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc - Bge-102在SAD和初始MAD队列中的耐受性良好，药代动力学特征支持每日一次口服给药","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124296489","title":"BioAge Labs Inc - 宣布Bge-102的积极中期1期数据显示其为一种新型脑穿透性Nlrp3抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1124296489","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124296489?lang=zh_cn&edition=full","pubTime":"2025-12-04 22:09","pubTimestamp":1764857355,"startTime":"0","endTime":"0","summary":"BioAge Labs Inc - 宣布Bge-102的积极中期1期数据显示其为一种新型脑穿透性Nlrp3抑制剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186878787","title":"异动解读 | 生物科技新星BioAge Labs纳斯达克上市首日大涨6.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186878787","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186878787?lang=zh_cn&edition=full","pubTime":"2024-09-27 21:36","pubTimestamp":1727444184,"startTime":"0","endTime":"0","summary":"9月27日,生物科技新星BioAge Labs Inc.在美国纳斯达克交易所成功挂牌上市,股价大涨6.36%,收于38.74美元,引发市场广泛关注。BioAge Labs主攻代谢疾病等人类衰老相关疾病的治疗领域,其主要候选药物azelaprag在多项临床试验中表现出良好的安全性和有效性。此外,生物科技公司是今年美国IPO市场的一大亮点,活跃的IPO市场为BioAge Labs上市大涨提供了良好环境。投资者偏好盈利前景明朗的公司,生物科技龙头BioAge Labs自然成为资金追捧对象。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163589295","title":"异动解读 | 生物科技新星BioAge Labs纳斯达克挂牌上市 股价大涨5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=1163589295","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163589295?lang=zh_cn&edition=full","pubTime":"2024-09-27 20:56","pubTimestamp":1727441784,"startTime":"0","endTime":"0","summary":"生物科技新星BioAge Labs Inc.于2024年9月26日在美国纳斯达克交易所成功挂牌上市,首日股价大涨5.73%,反映了投资者对该公司未来发展前景的乐观预期。BioAge Labs主攻代谢疾病等人类衰老相关疾病的治疗领域,其主要候选药物azelaprag是一种口服小分子,已在多项临床试验中表现出良好的安全性和有效性。据招股书披露,BioAge Labs虽然暂无营收,但已累计获得超过3亿美元融资,投资者包括知名风险投资机构Andreessen Horowitz、Khosla Ventures等。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2470971613","title":"生物科技公司BioAge Labs纳斯达克上市：市值6亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2470971613","media":"雷递网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470971613?lang=zh_cn&edition=full","pubTime":"2024-09-27 09:01","pubTimestamp":1727398919,"startTime":"0","endTime":"0","summary":"生物科技初创公司BioAge Labs（股票代码为：“BIOA”）昨日在美国纳斯达克上市，募资总额为1.98亿美元。BioAge Labs开盘价为22.5美元，较发行价上涨25%；收盘价为18.31美元，较发行价上涨1.72%；以收盘价计算，公司市值为6.16亿美元。","market":"us","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240927/6386302451252659998745633.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20240927/6386302451252659998745633.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n27839/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["NQmain","BIOA","PPT","PSQ","QLD","SQQQ","03086","BK1147",".IXIC","TQQQ","ARTL","QID","MNQmain","BK4007"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1174058188","title":"异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1174058188","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174058188?lang=zh_cn&edition=full","pubTime":"2024-09-27 00:16","pubTimestamp":1727367379,"startTime":"0","endTime":"0","summary":"在纳斯达克交易的生物科技公司BioAge Labs Inc. 股价今日大涨25%,引发了市场的广泛关注。从公司最新消息来看,这与其正在积极筹备的首次公开募股有直接关联。据悉,BioAge Labs计划以每股18美元的价格发行1100万股新股,募集资金高达1.98亿美元。BioAge Labs的主打产品Azelaprag是一种口服小分子药物,已在8个1期临床试验中展现出良好的安全性和耐受性。公司目前正在开展Azelaprag与现有减肥药联合用药的2期临床试验,有望成为全口服肥胖症联合疗法。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | BioAge Labs Inc.(BIOA.US)股价大涨25% 获资本市场看好减肥药研发前景","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2470813206","title":"减肥药研发公司BioAge Labs(BIOA.US)扩大发行规模至1100万股 IPO定价18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2470813206","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2470813206?lang=zh_cn&edition=full","pubTime":"2024-09-26 15:59","pubTimestamp":1727337555,"startTime":"0","endTime":"0","summary":"生物科技初创公司BioAge Labs正在筹划通过首次公开发行(IPO)筹集高达1.98亿美元的资金。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20240926/20240926155504_53537.png?x-oss-process=image/format,jpg/quality,Q_80","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20240926/20240926155504_53537.png?x-oss-process=image/format,jpg/quality,Q_80"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1187478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BIOA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2468083543","title":"生物科技初创公司BioAge Labs(BIOA.US)IPO定价17-19美元/股 拟筹资1.35亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468083543","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468083543?lang=zh_cn&edition=full","pubTime":"2024-09-19 14:50","pubTimestamp":1726728600,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物科技初创公司BioAge Labs于周三公布了其 IPO 条款，该公司计划以 17 至 19 美元的价格区间发行 750 万股股票，筹集 1.35 亿美元。按照提议的范围的中间值，BioAge Labs 的市值将达到 6.02 亿美元。BioAge Labs的主要关注点是代谢疾病，这是全球最大的医疗保健挑战之一。BioAge Labs的主要候选产品 Azelaprag是一种口服小分子，在8个 1 期临床试验中，265 名受试者的耐受性良好。BioAge Labs在2022年、2023年运营亏损分别为3997万美元、4840万美元;净亏损分别为3972万美元、6385万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1184507.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIOA","159837"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.0368},{"period":"1month","weight":0.1822},{"period":"3month","weight":-0.0401},{"period":"6month","weight":1.4538},{"period":"1year","weight":3.797},{"period":"ytd","weight":0.4467}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0819},{"period":"3month","weight":0.0896},{"period":"6month","weight":0.1047},{"period":"1year","weight":0.2649},{"period":"ytd","weight":0.0886}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BioAge Labs, Inc.于2015年4月1日在特拉华州注册成立。他们是一家临床阶段的生物制药公司，通过针对人类衰老的生物学特性，开发治疗肥胖等代谢性疾病的候选产品。他们的技术平台和差异化的人类数据集使他们能够根据对驱动衰老的分子变化的见解来识别有前景的靶点。他们的主要关注点是代谢性疾病，这是全球最大的医疗保健挑战之一。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供BioAge Labs Inc.(BIOA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供BioAge Labs Inc.(BIOA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}